Brawn Biotech Ltd. engages in the manufacture, contracting, and supply of pharmaceutical and medical products. The company is headquartered in New Delhi, Delhi. The firm's pharmaceutical products cover all product segments, antibacterials, cardiovasculars, antidiabetics, analgesics, gastrointestinals, antifungals, skin care, antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. Its products include Sefix-400 Capsules, Sefix-200 Capsules, Celevran Cream W/C (25GM), Voltran Gel W/C (25GM), Folic Acid Tablets 8P 5MG, Ponstran Capsules 250MG, Fugeran Cream W/C (15GM), Stopin Tablets, Cefixime Tablets 100MG (1*10), Cefixime Tablets USP 200MG (1*10), Carbramazepine 200 MG IP Tab, Potassium Chloride for Injection 15% 150mg/ml USP (10 ML), Promethazine HCL Injection 25 MG/ML, Allopurinol 100mg IP Tab, Carbamazepine 100 mg IP Tab Feme Tab, Bromex Liquid, Salbutamol 4 mg IP Tab, Chlorpheniramine Maleate 4mg Tab, Pheniramine Maleate 25mg Tab, Eracef 500 mg, Erazide 1 Gm Injection, Hyoscine Butyl Bromide (1 ml) IP Inj and Alprazolam 0.5 Mg Tab.
Loading chart…
This company hasn't held an earnings call in the last six months, so there's no recent commentary from management. Our deep dives are built on what management actually said, so we haven't prepared one.
15 fields couldn't be derived. The company was scraped before the cash-flow and balance-sheet rows were captured. Re-running an analysis will refresh these.